# Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma

> **NCT00308607** · PHASE2 · COMPLETED · sponsor: **University of Turku** · enrollment: 27 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Bevacizumab (Avastin)
- **DRUG:** dacarbazine
- **DRUG:** interferon-alfa-2a (Roferon-A)

## Key facts

- **NCT ID:** NCT00308607
- **Lead sponsor:** University of Turku
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-12
- **Final completion:** 2009-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2009-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00308607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00308607, "Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00308607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*